Eficiența imatinibului ca primă linie terapeutică în faza cronică a leucemiei mieloide cronice

Abstract

The purpose of the targeted therapy with imatinib (glivec) in CML is to induce a complete hematological response (RHC) after 3 months, a complete cytogenetic response after 12 months and major molecular response after 18 months. The aim of this study was to analyse the rates of cytogenetic response and the correlation relative risc-cytogenetic response. In this study imatinib as a first line therapy was used at 26 patients (11 females and 15 males). The cytogenetic exam made at 6 months showed that 64,7% of patients achieved RCM, while at 12 months 76.9% of patients achieved RCM . The average period to follow the patients was 21,8 months (minimum 6 months – maximum 72 months), the survival rate being 96,15%. In conclusion, imatinib as a first line therapy associated with the use of the criteria for monitoring and treatment recommended by European LeukemiaNet optimize the results and improve the overall survival. The results of this study should be analyzed with the mention of the limited number of cases as a first line therapy.